Advertisement

Antihypertensive Agents in the Dialysis Patient

  • Michelle A. FravelEmail author
  • Elizabeth Bald
  • Mony Fraer
Antihypertensive Agents: Mechanisms of Drug Action (Michael E. Ernst, Section Editor)
  • 98 Downloads
Part of the following topical collections:
  1. Topical Collection on Antihypertensive Agents: Mechanisms of Drug Action

Abstract

Purpose of Review

Hypertension and antihypertensive drug utilization are remarkably prevalent in ESRD patients. Management of blood pressure elevation in this population is complicated by many factors, including a multidimensional etiology, challenges in obtaining accurate and appropriately timed blood pressure measurements, highly specific drug dosing requirements, and a paucity of outcomes-based evidence to guide management decisions. The purpose of this review is to summarize and apply knowledge from existing clinical trials to enhance safe and effective use of antihypertensive agents in dialysis patients.

Recent Findings

Two meta-analyses have established the benefit of antihypertensive therapy in ESRD. Data supporting the use of one antihypertensive class over another is less robust; however, beta-blockers have more clearly demonstrated improved cardiovascular outcomes in prospective randomized trials. Interdialytic home blood pressure monitoring has been demonstrated to be better associated with cardiovascular outcomes than clinic pre- or post-dialysis readings and should ideally be considered as a routine part of blood pressure management in this population.

Summary

As data from small trials provides limited guidance for the management of hypertension in ESRD, more research is needed to guide medication selection and utilization. Specifically, large prospective randomized trails comparing cardiovascular outcomes of various medication classes and differing blood pressure targets are needed.

Keywords

Hypertension Hemodialysis Chronic kidney disease Antihypertensive agents 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34:381–90.CrossRefGoogle Scholar
  2. 2.
    Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–7.CrossRefGoogle Scholar
  3. 3.
    Sarafidis PA, Mallamaci F, Loutradis C, Ekart R, Torino C, Karpetas A, et al. Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrol Dial Transplant. 2018.  https://doi.org/10.1093/ndt/gfy147.
  4. 4.
    Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2017.Google Scholar
  5. 5.
    Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. Int J Cardiol. 2010;142:80–6.CrossRefGoogle Scholar
  6. 6.
    Tong YQ, Hou HM. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol. 2007;27:63–9.CrossRefGoogle Scholar
  7. 7.
    Kornerup HJ, Schmitz O, Danielsen H, Pedersen EB, Giese J. Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contrib Nephrol. 1984;41:123–7.CrossRefGoogle Scholar
  8. 8.
    Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad- Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.CrossRefGoogle Scholar
  9. 9.
    Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–9.CrossRefGoogle Scholar
  10. 10.
    Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens (Greenwich). 2012;14:799–801.CrossRefGoogle Scholar
  11. 11.
    Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P, Tsioufis C. Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol. 2014;12:47–54.CrossRefGoogle Scholar
  12. 12.
    • Sarafidis P, Persub A, Agarwal R, Burnierf M, de Leeuwg P, Ferroi C, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association ^ European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the kidney working group of the European Society of Hypertension (ESH). J Hypertens. 2017;35:657–76 This position paper is a comprehensive review of management of hypertension in dialysis, including etiology, blood pressure measurement, suggested blood pressure targets, utilization of antihypertensive agents, recommended first and second-line therapies, and opportunities for future research.CrossRefGoogle Scholar
  13. 13.
    Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Phys. 1991;261:E642–6.CrossRefGoogle Scholar
  14. 14.
    Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61:44–56.CrossRefGoogle Scholar
  15. 15.
    Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14:185–90.CrossRefGoogle Scholar
  16. 16.
    Chiu Y, Teitelbaum I, Misra M, de Leon E, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089–96.CrossRefGoogle Scholar
  17. 17.
    • Levin NW, Kotanko P, Eckardt K, Kasiske BL, Chazot C, Cheung A, et al. Blood pressure in chronic kidney disease stage 5D – report from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2010;77(4):273–84.  https://doi.org/10.1038/ki.2009.469 This position paper is a comprehensive review of management of hypertension in dialysis, including etiology, blood pressure measurement, utilization of antihypertensive agents, and opportunities for future research.CrossRefPubMedGoogle Scholar
  18. 18.
    Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53:500–7.CrossRefGoogle Scholar
  19. 19.
    Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol. 2002;15:655–60.PubMedGoogle Scholar
  20. 20.
    Torino C, Gargani L, Sicari R, Letachowicz K, Ekart R, Fliser D, et al. The agreement between auscultation and lung ultrasound in hemodialysis patients: the LUST study. Clin J Am Soc Nephrol. 2016;11:2005–11.CrossRefGoogle Scholar
  21. 21.
    Agarwal R, Bouldin JM, Light RP, Garg A. Probing dry-weight improves left ventricular mass index. Am J Nephrol. 2011;33:373–80.CrossRefGoogle Scholar
  22. 22.
    Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant. 2009;24:956–62.CrossRefGoogle Scholar
  23. 23.
    de Paula FM, Peixoto AJ, Pinto LV, Dorigo D, Patricio PJ, Santos SF. Clinical consequences of an individualized dialysate sodium prescrip- tion in hemodialysis patients. Kidney Int. 2004;66:1232–8.CrossRefGoogle Scholar
  24. 24.
    Munoz MJ, Bayes LY, Sun S, Doss S, Schiller B. Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study. Am J Kidney Dis. 2011;58:956–63.CrossRefGoogle Scholar
  25. 25.
    •• Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228–34 This prospective trial helped to establish the utility of home blood pressure measurement as an accurate means for monitoring blood pressure in ESRD based on correlation with cardiovascular outcomes.CrossRefGoogle Scholar
  26. 26.
    Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giacone G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens. 1999;17:1751–8.CrossRefGoogle Scholar
  27. 27.
    Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2006;1:389–98.CrossRefGoogle Scholar
  28. 28.
    Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. ‘U’ curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561–9.CrossRefGoogle Scholar
  29. 29.
    •• Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009–15 This meta-analysis, including nine clinical trials, was the first of its kind published to establish the cardiovascular benefit of antihypertensive agents in ESRD patients.CrossRefGoogle Scholar
  30. 30.
    •• Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009;53:860–6 This meta-analysis, including five clinical trials, helped to confirm the cardiovascular benefit of antihypertensive agents in ESRD patients and highlighted potentially greater benefit in dialysis patients with hypertension specifically.CrossRefGoogle Scholar
  31. 31.
    Wanner C, Krane V, Marz W. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;53:238–48.CrossRefGoogle Scholar
  32. 32.
    Fellstrom BC, Jardine AG, Schmieder RE. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.CrossRefGoogle Scholar
  33. 33.
    Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefGoogle Scholar
  34. 34.
    Mallappallil M, Fishbane S, Wanchoo R, Lerma E, Roche-Recinos A, Salifu M. Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists. BMC Nephrol 2018:19.  https://doi.org/10.1186/s12882-018-0943-0.
  35. 35.
    Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71(6):1269–324.  https://doi.org/10.1161/hyp.0000000000000066.CrossRefPubMedGoogle Scholar
  36. 36.
    Aronoff GR. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2009.Google Scholar
  37. 37.
    Mallamaci F, Zoccali C. Hypertension. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.Google Scholar
  38. 38.
    Agarwal R, Georgianos PI. Pharmacotherapy of hypertension in chronic dialysis patients. Clin J Am Soc Nephrol. 2016;11:2062–75.  https://doi.org/10.2215/CJN.00870116.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    •• Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo controlled trial. J Am Coll Cardiol. 2003;41:1438–44 This is one of very few prospective, randomized controlled, double blind studies examining antihypertensive agents in ESRD to find clinically and statistically significant benefit with treatment.CrossRefGoogle Scholar
  40. 40.
    Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29:672–81.CrossRefGoogle Scholar
  41. 41.
    Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int. 1999;55:1528–35.CrossRefGoogle Scholar
  42. 42.
    Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ, et al. Beta-blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26:987–96.CrossRefGoogle Scholar
  43. 43.
    •• Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23:3605–12 This is one of very few prospective, randomized controlled, double blind studies examining antihypertensive agents in ESRD; clinically and statistically significant benefit with treatment was found.CrossRefGoogle Scholar
  44. 44.
    Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis – a randomized study. Nephrol Dial Transplant. 2006;21:2507–12.CrossRefGoogle Scholar
  45. 45.
    Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008;69:425–32.CrossRefGoogle Scholar
  46. 46.
    Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501–6.CrossRefGoogle Scholar
  47. 47.
    Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis. 2001;38:1245–50.CrossRefGoogle Scholar
  48. 48.
    Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44:404–10.CrossRefGoogle Scholar
  49. 49.
    Bomback AS. Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif. 2016;41:166–70.CrossRefGoogle Scholar
  50. 50.
    Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–36.CrossRefGoogle Scholar
  51. 51.
    Lin C, Zhang Q, Zhang H, Lin A. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo- controlled study. J Clin Hypertens (Greenwich). 2016;18:121–8.CrossRefGoogle Scholar
  52. 52.
    Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602–8.CrossRefGoogle Scholar
  53. 53.
    Brest UH. ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST). ClinicalTrials.gov: Bethesda (MD): National Library of Medicine (US). 2018. https://clinicaltrials.gov/ct2/show/NCT01848639. Accessed 7 Nov 2018.
  54. 54.
    Medcalf JF, Harris K, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59:1128–33.CrossRefGoogle Scholar
  55. 55.
    Ahmed S, Guffey D, Minard C, Workeneh B. Efficacy of loop diuretics in the management of undocumented patients with end-stage renal disease. Am J Emerg Med. 2016;34:1552–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Michelle A. Fravel
    • 1
    Email author
  • Elizabeth Bald
    • 2
  • Mony Fraer
    • 3
  1. 1.Department of Pharmacy Practice and Science, College of PharmacyThe University of IowaIowa CityUSA
  2. 2.Department of Pharmaceutical CareUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  3. 3.Division of Nephrology and Hypertension, Department of Internal Medicine, Carver College of MedicineThe University of IowaIowa CityUSA

Personalised recommendations